Senping Cheng

Senping Cheng is the founder and CEO of Triastek (三迭纪), a company positioned as a global leader in 3D pharmaceutical printing . Under her leadership, Triastek has developed MED® 3D printing technology for drug development and manufacturing, including a GMP-compliant continuous production center with annual capacity of 75 million tablets . The company has secured three FDA IND approvals for its proprietary products and entered partnerships with major pharmaceutical firms including Boehringer Ingelheim, Merck, and Eli Lilly . Cheng holds a doctorate degree and has been featured in Yunqi Capital's founder interview series, where she described Triastek's mission as bringing "meaningful, valuable 3D-printed drugs" to patients . In a 2025 Yunqi Capital survey of tech founders, she identified "advance" as her strategic choice for the year, emphasizing that "only through development can we break the deadlock" .